In this section you will find the latest Bayer Schering Pharma press releases for the United Kingdom.
If you have a particular enquiry about any of these releases then please contact us on the telephone number or e-mail address below:-
Tel: 01635 563198
8th June 2009
New combined oral contraceptive pill offers more choice to meet the individual needs of women today. >>more
19th May 2009
Positive data from a phase II trial with Bayer Schering Pharma’s oral agent riociguat for the treatment of two different forms of pulmonary hypertension (PH); chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH); were presented today at the American Thoracic Society (ATS) international conference in San Diego, USA. >>more
6th May 2009
Patients denied chance for extra time with family and loved ones after initial refusal to fund first systemic therapy proven to extend overall survival.>>more
28th April 2009
Today the National Institute for Health and Clinical Excellence (NICE) announced the Final Appraisal Determination (FAD) for Nexavar® (sorafenib), Sutent® (sunitinib), Avastin® (bevacizumab) and Torisel® (temsirolimus) in advanced kidney cancer. NICE has not recommended sorafenib, bevacizumab and temsirolimus as first line treatment option for kidney cancer. Furthermore, it does not recommend sorafenib or sunitinib for second line treatment for renal cell carcinoma (RCC) patients.>>more
23rd April 2009
The first ever UK TV advertisement campaign for emergency contraceptive pill (ECP), Levonelle® One Step, launches today.>>more
22nd April 2009
Without preventative treatment, 45,000 people undergoing elective hip or knee replacement every year in England could develop a potentially fatal blood clot. NICE now recommends Xarelto® – a new, oral anticoagulant, up to 70% more effective at reducing blood clots than the current gold standard (injectable enoxaparin).>>more
31st March 2009
Bayer Schering Pharma (BSP), (the prescription medicines arm of Bayer HealthCare in the UK) is to distribute selected products (BSP Products) under a new reduced wholesaler model, with Alliance Healthcare (Distribution) Limited (UniChem), Phoenix Healthcare Distribution Limited and AAH Pharmaceuticals Limited, effective from 1st July 2009. >>more
9th March 2009
The SMC has today accepted Nebido® (testosterone undecanoate) for use in Scotland for the treatment of hypogonadism, also known as Testosterone Deficiency Syndrome (TDS), when testosterone deficiency has been confirmed by clinical features and biochemical tests.>>more
4th March 2009
The National Institute for Health and Clinical Excellence (NICE) has issued an initial positive opinion on the new oral anticoagulant Xarelto® for the prevention of potentially fatal blood clots after elective hip or knee replacement surgery.>>more
18th February 2009
Based on the positive findings of the clinical development phase II trial, Bayer Schering Pharma has received ethical approval from the Cambridgeshire 1 Research Ethics Committee in the United Kingdom to begin the phase III program for its oral agent riociguat.>>more
